About Us
Treo Ventures (formerly known as Strategic Healthcare Investment Partners – S.H.I.P.) was established in 2018 to focus on medical device and digital health innovation targeting large unmet needs.
About Us
Treo Ventures (formerly known as Strategic Healthcare Investment Partners – S.H.I.P.) was established in 2018 to focus on medical device and digital health innovation targeting large unmet needs.
Founding General Partners Mudit Jain, previously with Johnson & Johnson’s venture arm, JJDC, and Synergy Life Science Partners, and Brad Vale, who previously led JJDC, established Treo Ventures in 2018 to focus on medical device and digital health innovation targeting large unmet needs. They were joined by Tracy Pappas in 2020.
The Treo team brings more than 90 years of cumulative healthcare experiences in investing and operational roles, across early and commercial stage companies. We have invested globally in 40+ companies through multiple market cycles. We worked together on a number of healthcare investments over the last 12 years prior to forming Treo Ventures. We bring a unique set of investing experiences from one of the largest strategic healthcare funds JJDC, which maintains a portfolio of over $1B and annually invests more than $200 million in medical devices, biotech, and consumer health, and private venture investing experiences at Synergy Life Science Partners, a top performing venture capital fund that generated multiple medical device Unicorns.
The Treo team has been involved in some of the premium healthcare companies bringing novel technologies to market and has played an active and important role from founding companies to liquidity via trade sales to multiple strategics and IPOs. Our experiences on private company and public company boards gives us a unique vantage point in our active involvement with portfolio companies. In addition, our scientific and commercial backgrounds along with global relationships have helped us play an important role in consistently building some of the most successful healthcare companies over last two decades.
We focus on medical technology investments in companies targeting large unmet clinical needs. We will invest in high growth areas and in companies solving major clinical problems while balancing that with focused capital efficient development plans. We take a balanced approach in building our portfolio with some early stage investments, where the prior seed stage investment has proved the feasibility of a concept, and some later stage investments, where clinical data has shown efficacy and the company is in a “scale up for commercialization” mode.
Our presence in US and Ireland, provides a large geographical footprint to support healthcare innovation globally.
We also invest in opportunities generated by NuXcel, our own medical device accelerator with a presence in Silicon Valley, Minneapolis, and Ireland.
Treo leverages its relationships and unique set of LPs to improve the speed and quality of development of new products and their commercialization globally.
